Anticoagulant effects of protamine sulfate in a canine model.
Protamine sulfate is considered a weak anticoagulant, yet little is known concerning the mechanism of this effect or its relation to prior heparin exposure. This investigation defined the influence of increasing doses of protamine, with and without prior heparin anticoagulation, on the activated clotting time (ACT), thrombin clotting time (TCT), prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen level, platelet count, and platelet aggregation to ADP in dogs (n = 8). Four doses of intravenous protamine sulfate (1.5, 3.0, 6.0, and 15.0 mg/kg) were studied in each animal, with at least 5 days between individual studies. Four dogs received heparin, 150 IU/kg 10 min prior to protamine sulfate administration, and four dogs received protamine sulfate alone. Protamine sulfate caused anticoagulation, both in the presence and absence of heparin, with significant changes occurring in the ACT, PTT, platelet count, and platelet aggregation. Relevant changes did not occur in the TCT, PT, or fibrinogen levels. Platelet effects were capable of causing bleeding with standard or excess use of protamine sulfate, especially if platelet numbers were already decreased, as might occur in surgical procedures where thrombocytopenia commonly accompanies major blood loss and replacement. The ACT, reflecting both the coagulation cascade and platelet function, was the test most profoundly affected by protamine overdosage, and therefore may be misleading as a measure of protamine reversal of heparin. The TCT, which is sensitive to heparin anticoagulation but not protamine-induced anticoagulation, should be more accurate in differentiating inadequate heparin reversal from the effects of excess protamine.
Kresowik
T F
TF
Department of Surgery, University of Michigan Medical School, Ann Arbor.
Wakefield
T W
TW
Fessler
R D
RD
Stanley
J C
JC
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D001780:Blood Coagulation Tests; D004285:Dogs; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006493:Heparin / Q000494:pharmacology; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count / Q000187:drug effects; D011479:Protamines / Q000494:pharmacology*; D011517:Prothrombin Time; D013918:Thrombin Time
D000925:Anticoagulants; D011479:Protamines; D005340:Fibrinogen; D006493:Heparin